Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood-Testing Device Captures Cancer Cells

By LabMedica International staff writers
Posted on 11 Apr 2011
A newer version of a device can detect single cancer cells in a blood sample, potentially allowing doctors to determine quickly whether a tumor is metastasizing. More...


The microfluidic device is studded with carbon nanotubes, which are tiny, hollow cylinders whose walls are lattices of carbon atoms that collect cancer cells eight times better than the original version.

Scientists at the Massachusetts General Hospital, (Charlestown, MA, USA), collaborating with engineers at the Massachusetts Institute of Technology, Cambridge, MA, USA), have refined the cell capturing device. They developed the use of micropatterned carbon-nanotube forests confined inside microfluidic channels for mechanically and/or chemically capturing particles ranging over three orders of magnitude in size.

The team placed various geometries of carbon nanotube forest into the microfluidic device. As in the original device, the surface of each tube can be coated with antibodies specific to cancer cells. However, because the fluid can go through the forest geometries as well as around them, there is much greater opportunity for the target cells or particles to be caught. The scientists can customize the device by attaching different antibodies to the nanotubes' surfaces. Changing the spacing between the nanotube geometric features also allows them to capture different sized objects from tumor cells, about a micrometer in diameter, down to viruses, which are only 40 nm.

Circulating tumor cells (CTC), that have broken free from the original tumor are normally very hard to detect, because there are so few of them, usually only several cells per one mL of sample of blood, which normally contains billions of normal blood cells. By detecting these breakaway cells the physician can determine whether a cancer has metastasized. The scientists are now beginning to work on tailoring the device for human immunodeficiency virus (HIV) diagnosis. The original cancer-cell-detecting device is now being tested in several hospitals and may be commercially available within the next few years.

The scientists envisage the creation of new families of devices using this technique for a very broad range of applications. These include lab-on-a-chip devices for blood analysis to monitor patients at the point-of-care; ultra rapid cell sorters to detect rare cells in circulation for diagnostics, such as cancer, prenatal, and infections; high-throughput filters for pathogen depletion; and isolation of bacteria and viruses for diagnosing infectious diseases. The article describing the device was published online in March 17, 2011, in the journal Small.

Related Links:

Massachusetts General Hospital
Massachusetts Institute of Technology



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.